by EpicentRx | Jun 21, 2024 | Media
by EpicentRx | Jun 14, 2024 | Conferences
November 5-7 , 2022 – McCormick Place, Chicago, IL View Poster
by EpicentRx | May 23, 2024 | 2024, Press Releases
Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them...
by EpicentRx | May 7, 2024 | Conferences
May 31-June 4, 2024 – Chicago, Illinois Oral Presentation: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. Learn more
